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Abstract  3-Methoxyphencyclidine (3-MeO-PCP) and 3-methoxyrolicyclidine (3-MeO-
PCPy) are two new psychoactive substances (NPS). The aims of the present study were the 
elucidation of their metabolic fate in rat and pooled human liver microsomes (pHLM), the 
identification of the cytochrome P450 (CYP) isoenzymes involved, and the detectability using 
standard urine screening approaches (SUSA) after intake of common users’ doses using gas 
chromatography-mass spectrometry (GC-MS), liquid chromatography-multi-stage mass 
spectrometry (LC-MSn), and liquid chromatography-high-resolution tandem mass 
spectrometry (LC-HR-MS/MS). For metabolism studies, rat urine samples were treated by 
solid phase extraction or simple precipitation with or without previous enzymatic conjugate 
cleavage. After analyses via LC-HR-MSn, the phase I and II metabolites were identified. Both 
drugs showed multiple aliphatic hydroxylations at the cyclohexyl ring and the heterocyclic 
ring, single aromatic hydroxylation, carboxylation after ring opening, O-demethylation, and 
glucuronidation. The transferability from rat to human was investigated by pHLM 
incubations, where O-demethylation and hydroxylation were observed. The involvement of 
the individual CYP enzymes in the initial metabolic steps was investigated after single CYP 
incubations. For 3-MeO-PCP, CYP 2B6 was responsible for aliphatic hydroxylations and 
CYP 2C19 and CYP 2D6 for O-demethylation. For 3-MeO-PCPy, aliphatic hydroxylation 
was again catalyzed by CYP 2B6 and O-demethylation by CYP 2C9 and CYP 2D6. As only 
polymorphically expressed enzymes were involved, pharmacogenomic variations might 
occur, but clinical data are needed to confirm the relevance. The detectability studies showed 
that the authors’ SUSAs were suitable for monitoring the intake of both drugs using the 
identified metabolites. 
 
Keywords: new psychoactive substances; 3-MeO-PCP; 3-MeO-PCPy; metabolism; LC-HR-
MSn; screening 
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1. INTRODUCTION 
 
The new psychoactive substances (NPS) 3-methoxyphencyclidine (3-MeO-PCP, Fig. 1a) and 
3-methoxyrolicyclidine (3-MeO-PCPy, Fig. 1b) are derivatives of phencyclidine (PCP, Fig. 
1c), which is known for over 60 years. As reviewed by Morris and Wallach [1], PCP was 
synthesized first in 1956 and approved in the following years as a non-narcotic anesthetic in 
veterinary medicine under the trade names Sernyl or Sernylan. The use for human treatment 
was short-lived and limited due to unfavorable side effects such as agitation, hallucination, 
and delirium-like conditions. In 1967, phencyclidine appeared as a street drug in the USA 
under names such as “Peace Pill”, “Angle Dust”, “Blue Dust”, or “Killer Weed”, and in 
Germany, recreational use appeared in 1977. To overcome national narcotic laws, the 
structure of phencyclidine was continuously modified and included modifications of the 
amine moiety, the phenyl, or the piperidine ring [2,3]. Since the derivative 
phenylcyclohexylpyrrolidine (also known as rolicyclidine or PCPy, Fig. 1d) has been 
scheduled in the USA in the 1970s, other modifications were encountered that included 
alkoxy derivatives [1,4]. According to reports from the European Monitoring Center for 
Drugs and Drug Addiction (EMCDDA), 3-MeO-PCP [5] and 4-MeO-PCP have been 
identified in 2012 and 2011, respectively [6,7]. 3-MeO-PCP and 3-MeO-PCPy are usually 
snorted, smoked as a PCP-laced marijuana cigarette, ingested as a tablet, or injected 
intravenously or subcutaneously [1]. Effects such as euphoria and analgesia might share some 
similarities with PCP [8,9] although some differences might also exist regarding their 
psychopharmacological profile [1]. Mechanisms of action include uncompetitive antagonism 
of the excitatory N-methyl-D-aspartate (NMDA) receptor and reuptake inhibition of 
noradrenaline, serotonin, and dopamine [10,11]. 
However, a current challenge is that such NPS cannot be detected reliably in 
toxicological urine screening procedures as excretion products are usually unknown. 
Therefore, the aims of our study were the elucidation of the phase I metabolism of 3-MeO-
PCP and 3-MeO-PCPy in rat and human liver microsomes using LC-(high resolution, HR)-
MSn, the identification of the involved CYP isoenzymes, and the investigation of the 
detectability of common users’ doses in standard urine screening approaches (SUSA) using 
gas chromatography-mass spectrometry (GC-MS), liquid chromatography-multi-stage mass 
spectrometry (LC-MSn), and liquid chromatography-high-resolution tandem mass 
spectrometry (LC-HR-MS/MS).  
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2. EXPERIMANTAL PROCEDURES 
 
2.1. Chemicals and reagents 
 
3-MeO-PCP and 3-MeO-PCPy were synthesized and characterized as reported previously 
[12]. NADP+ and isocitrate dehydrogenase were obtained from Biomol (Hamburg, Germany), 
Isolute Confirm HCX cartridges (130 mg, 3 mL) from Biotage (Uppsala, Sweden), 
ammonium sulfate from Fluka (Buches, Switzerland), acetonitrile (LC-MS grade), 
ammonium formate (analytical grade), dichloromethane, diethyl ether, formic acid (LC-MS 
grade), isocitrate, magnesium chloride, pyridine, superoxide dismutase, sodium hydroxide, 
and Tris buffer from Sigma-Aldrich (Taufkirchen, Germany), acetic anhydride, acetic acid, 
ethyl acetate, glucuronidase/arylsulfatase, hydrochloric acid (37%), isopropanol, methanol 
(LC-MS grade), aqueous ammonia (32%), and sodium dihydrogen phosphate and all other 
chemicals and biochemicals from VWR (Darmstadt, Germany). The baculovirus-infected 
insect cell microsomes (Supersomes), containing 1 nmol/mL of human cDNA-expressed CYP 
1A2, CYP 2A6, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, or 2 nmol/mL CYP 
2E1, CYP 3A4, CYP 3A5, and pooled human liver microsomes (pHLM, 20 mg microsomal 
protein/mL, 400 pmol total CYP/mg protein), were obtained from BD Biosciences 
(Heidelberg, Germany). After delivery, the microsomes were thawed at 37°C, aliquoted, snap-
frozen in liquid nitrogen, and stored at -80°C until use.  
 
2.2. Urine samples 
 
Studies were performed using rat urine samples from male Wistar rats (Charles River, 
Sulzfeld, Germany) for toxicological diagnostic reasons according to the corresponding 
German law. The compounds were administered once in an aqueous suspension by gastric 
intubation in a dose of 10 mg/kg body mass (BM) for the identification of the metabolites and 
once in a 1 mg/kg BM representing common users’ doses, calculated and downscaled using 
an allometric dose-by-factor approach described by Sharma and McNeill [13]. 
The rats were housed in metabolism cages for 24 h, having water ad libitum. Urine was 
collected separately from feces over a 24-h period. Blank urine samples were collected before 
drug administration to confirm the absence of interfering compounds. The samples were 
directly analyzed and then stored at -20°C. 
 
2.3. Sample preparation for identification of phase I and II metabolites by LC-HR-MSn 
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The first of two preparations of high dosed rat urine samples was performed in analogy to a 
published procedure [14]. A 2-mL aliquot of urine sample was adjusted to pH 5.2 with 1 M 
acetic acid, a 50-µL aliquot of a mixture (100,000 Fishman units per mL) of glucuronidase 
(EC No. 3.2.1.31) and arylsulfatase (EC No. 3.1.6.1) from Helix pomatia L was added, and 
subsequently incubated at 50°C for 2 h. Afterwards, the sample was centrifuged at 5,000 rpm 
for 5 min, the supernatant loaded onto a cation exchange Confirm HCX solid phase extraction 
(SPE) cartridge, previously conditioned with 1 mL methanol and 1 mL water. After passing 
the SPE cartridge, washing steps were performed with 1 mL water, 1 mL 0.01 M hydrochloric 
acid, 1 mL water, and 1 mL methanol. The retained basic compounds were eluted using 1 mL 
of a freshly prepared mixture of methanol/32% aqueous ammonia (98:2, v/v). The eluate was 
subsequently evaporated to dryness under a stream of nitrogen at 70°C and  reconstituted with 
50 µL of methanol. A 10-µL aliquot was injected for LC-HR-MSn analysis. Conditions were 
as described below. 
The second sample preparation was performed according to Wissenbach et al. [15]. A 
100-µL aliquot of the high dosed rat urine sample was mixed with 500 µL of acetonitrile and 
vortexed for 2 min. Afterwards, the sample was centrifuged for 2 min at 10,000 g, the 
supernatant evaporated to dryness under a gentle stream of nitrogen at 70°C, and the residue 
reconstituted with a mixture of mobile phase A and B (1:1, v/v) described below for LC-MSn. 
A 5-µL aliquot was injected onto the LC-HR-MSn system. Conditions were as described 
below. 
 
2.4. Microsomal incubations for pHLM and initial CYP activity screening studies 
The incubations were performed according to a published procedure [14] using CYP 1A2, 
CYP 2A6, CYP 2B6, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1, CYP 3A4, CYP 
3A5, or pHLM for 30 min at 37°C. The final incubation mixture consisted of 90 mM buffer 
(Tris buffer for CYP 2A6 and CYP 2C9, phosphate buffer for all other incubations), 25 µM 
drug as substrate, 200 U/mL superoxide dismutase, 75 pmol/mL CYP isoenzyme, and 
regenerating system consisted of 5 mM magnesium chloride, 5 mM isocitrate, 1.5 mM 
NADP+, and 0.5 U/mL isocitrate dehydrogenase in a final volume of 50 µL. Reaction was 
initiated by addition of regenerating system and stopped with 50 µL ice-cold acetonitrile. 
Afterwards, the sample was centrifuged for 5 min at 10,000 g, the supernatant transferred to a 
glass vial, and a 10-µL aliquot was injected onto the LC-MSn system. Conditions were as 
described below. 
 
 
2.5. Identification of phase I and II metabolites in urine by LC-HR-MSn  
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Phase I and II metabolites in urine were identified by a system consisted of an Orbitrap Velos 
Pro (Thermo Fischer Scientific, Dreieich, Germany) equipped with a heated electrospray 
ionization (HESI)-II source coupled to a Dionex Ultimate 3000 LC system. The used 
conditions and gradient elution were according to a published procedure [14], gradient 
program was composed according to Wissenbach et al. [15]. A parent mass list was used 
containing proposed metabolites whereby the list was divided into two separate experiments 
to reduce the amount of preferred ions for monitoring. The system was running Thermo 
Scientific Xcalibur 2.2. 
 
2.6. Analysis of the metabolites in microsomal incubations by LC-MSn  
LC-MSn analysis of the metabolites in microsomal incubations was performed according to a 
published procedure [14]. The system consisted of a LXQ linear ion trap MS equipped with 
an HESI-II source coupled to an Accela LC system consisting of a degasser, a quaternary 
pump, and an autosampler (all from ThermoFisher Scientific, Dreieich, Germany). The 
gradient program was composed according to Wissenbach et al. [15] and the same as 
described for LC-HR-MSn. The System was running Thermo Scientific Xcalibur 2.0.7.  
 
2.7. GC-MS SUSA 
According to a published procedure [16], a 5-mL aliquot of the low dosed rat urine sample 
was divided into two aliquots, the first was submitted to acid hydrolysis for 15 min and 
basified to pH 9, followed by combining with the second and subsequent extraction with a 
dichloromethane-isopropanol-ethyl acetate mixture (1:1:3, v/v/v). After evaporation, the 
residue was acetylated with an acetic anhydride-pyridine mixture (3:2, v/v) under microwave 
irradiation, again evaporated and reconstituted in 100 µL of methanol. A 1-µL aliquot was 
injected onto the GC-MS system, consisted of a Hewlett-Packard (HP; Agilent, Waldbronn, 
Germany) 5890 Series II gas chromatograph combined with an Agilent 5972 MSD mass 
spectrometer running HP MS ChemStation (DOS series) B.02.05. GC and MS conditions 
were according to a published procedure [16]. 
The full scan data files were evaluated by use of the automated mass spectral 
deconvolution and identification system (AMDIS, http://chemdata.nist.gov/mass-spc/amdis/) 
in simple mode. The target library was a modified version of the Maurer/Pfleger/Weber 
MPW_2016 library [17]. The deconvolution settings were according to Meyer et al. [18]. 
 
2.8. LC-MSn SUSA 
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In accordance to Wissenbach et al. [19], a 100-µL aliquot of the low dosed urine sample was 
worked up as described for the identification of phase I and II metabolites in urine. A 10-µL 
aliquot was injected onto the LC-MSn system. Conditions were as described for analysis of the 
metabolites in microsomal incubations. 
For data acquisition, ThermoFisher ToxID 2.1.1 for automatic target screening in the 
MS2 screening mode was used. The settings were according to Wissenbach et al. [19]. ToxID 
was run automatically after file acquisition by using an Xcalibur processing method starting 
the software tool. The target library was a modified version of the Maurer/Wissenbach/Weber 
MWW_2014 library [20]. 
 
2.9. LC-HR-MS/MS SUSA 
 
In accordance to Helfer et al. [21], a 100-µL aliquot of the low dosed rat urine sample was 
mixed with 500 µL of acetonitrile and vortexed for 2 min. After centrifugation for 2 min at 
10,000 g, the supernatant was evaporated to dryness under a gentle stream of nitrogen at 
70 °C and the residue reconstituted with a mixture of mobile phase A and B (1:1, v/v) 
described below. A 10-µL aliquot was injected onto the LC-HR-MS/MS system, consisted of 
a Q-Exactive system equipped with an HESI-II source (ThermoFisher Scientific, Dreieich, 
Germany) coupled to an Accela LC system, consisting of a degasser, a quaternary pump, and 
an HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland). Gradient elution and 
MS conditions were according to a published procedure [21]. The System was running 
Thermo Scientific Xcalibur 3.0.63. For data acquisition, ThermoFisher TraceFinder Clinical 
Research 3.2 software was used as described by Helfer et al. [21]. 
 
2.10. Determination of the detection limits of the parent drugs in urine for SUSA 
 
For assessing the general performance of the SUSA, the determination of the limits of 
detection (LOD) for the parent drugs were determined [22]. For this purpose, 3-MeO-PCP and 
3-MeO-PCPy were spiked in rat urine in increasing concentrations, respectively, and analyzed 
via GC-MS, LC-MSn, and LC-HR-MS/MS SUSA. The concentration level with a signal-to-
noise of three was defined as LOD. 
 
 
 
3. RESULTS AND DISCUSSION 
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3.1. Identification of phase I and II metabolites by LC-HR-MSn 
 
With the SPE-based sample preparation, only basic compounds were retained leading to 
cleaner extracts. For the non-basic compounds and the phase II metabolites, the second 
sample preparation was performed after simple precipitation.  
The proposed structural formulas were deduced by comparing the spectra of the 
metabolites with those of the parent compounds. Precursor masses (PM) are from MS1 
spectra, fragment ions from MS2 spectra. All masses are given with the calculated exact 
masses. The phase I metabolites found for 3-MeO-PCP are shown in Table 1, those for 3-
MeO-PCPy in Table 2. The phase II metabolites found for 3-MeO-PCP are shown in Table 3, 
those for 3-MeO-PCPy in Table 4. Overall, for 3-MeO-PCP, 30 phase I and seven phase II 
metabolites, and for 3-MeO-PCPy, 26 phase I and eight phase II metabolites were detected. 
 
3.2. Proposed fragmentation patterns for identification of the phase I and II metabolites 
by LC-HR-MSn 
 
3.2.1. 3-MeO-PCP 
 
In general, the spectrum of the parent compound (no. 1 in Table 1) revealed a characteristic 
fragmentation pattern, whereby a benzylic cleavage led to a 3-methoxy-phenylcyclohexyl 
fragment represented by the fragment ion of m/z 189.1279 and a piperidine fragment 
represented by the fragment ion of m/z 86.0967. In cases where the 3-methoxy-
phenylcyclohexyl fragment was unchanged, fragment ions could be observed at m/z 189.1279 
(nos. 6, 13, 20, and 30), if monohydroxylated at m/z 205.1229 (nos. 7, 14, 15, and 24-29), if 
O-demethylated at m/z 175.1123 (nos. 2, 3, 8-10, and 16), and if hydroxylated and O-
demethylated at m/z 191.1072 (nos. 4, 5, 11, 12, 17-19, and 21-23). In cases where the 
piperidine fragment was unchanged, fragment ions could be observed at m/z 86.0970 (nos. 2, 
4, and 7), if monohydroxylated at m/z 102.0919 (nos. 3, 6, 11, 12, 14, and 15), and if 
dihydroxylated at m/z 118.0868 (nos. 8-10, 13, 17-19, and 24). Aliphatic hydroxylations were 
proposed by the elimination of water resulting in unsaturated fragments at m/z 187.1123 
(205.1229 – 18.0100 u; nos. 7, 14, 15, and 24-29), 173.0966 (191.1072 – 18.0100 u; nos. 4, 5, 
11, 12, 17, 19, and 21-23), and 84.0813 (102.0919 – 18.0100 u; nos. 3, 6, 11, 12, and 14).  
A metabolite with PM of m/z 260.2014 revealed a spectrum of an O-demethyl 
metabolite (no. 2) with a fragment ion of m/z 175.1123. Two hydroxy metabolites were 
revealed by PM of m/z 290.2120. One isomer revealed a piperidine-hydroxy metabolite (no. 
Accepted (uncorrected) for publication in Current Neuropharmacology (03 October 2016) 
	
9	
6) and one a cyclohexyl-hydroxy metabolite (no. 7). Four dihydroxy metabolites were 
revealed by PM of m/z 306.2069, one piperidine-dihydroxy (no. 13) and two isomeric 
cyclohexyl-hydroxy piperidine-hydroxy metabolites (nos. 14 and 15). One trihydroxy 
metabolite was revealed by PM of m/z 322.2018 representing a cyclohexyl-hydroxy 
piperidine-dihydroxy metabolite (no. 24). In addition, a hydroxylation at the α-position to the 
amine at the piperidine ring would led to a rather instable hemiaminal species followed by 
ring opening and oxidation to an aliphatic carboxy metabolite. This mechanism had already 
been described for PCP [23] and for diverse PCP derivatives by Sauer et al. [24-29]. The 
observed corresponding metabolites were a carboxy metabolite (no. 20) with PM of m/z 
320.1862, five isomeric methyl artifacts of carboxy cyclohexyl-hydroxy metabolites (nos. 25-
29) with PM of m/z 336.2175, and one carboxy alkyl-hydroxy metabolite (no. 30) with PM of 
m/z 336.2175. For metabolite no. 7, only one isomer was detected most probably due to the 
lower formation rate in contrast to the metabolites nos. 25-29. Moreover, in combination with 
O-demethylations ring opened methyl artifacts of carboxy metabolites could be observed with 
PM of m/z 306.2069 (no. 16) and after additional cyclohexyl-hydroxylation (methyl artifact) 
with PM of m/z 322.2018 (nos. 21-23). The existence of some carboxy metabolites was 
proposed after finding artificially formed methyl ester structures. One explanation for these 
formations could be a methylation of the carboxy group and nucleophilic attack during the 
work-up procedure, where the samples were evaporated in methanol at 70°C. Further 
confirmation was obtained when methanol was replaced with ethanol, leading to ethyl ester 
structures giving spectra with methylene shifts of the corresponding fragment ions. 
Combinations of O-demethylation and hydroxylation could also be proposed. Two O-
demethyl hydroxy isomers occurred with PM of m/z 276.1964, in particular one piperidine- 
(no. 3) and one cyclohexyl-hydroxy metabolite (no. 4), and five O-demethyl dihydroxy 
metabolites with PM of m/z 292.1913. Three isomers were observed with both hydroxy 
groups at the piperidine ring (nos. 8-10) and two isomers with one hydroxy group at the 
piperidine and the cyclohexyl ring, respectively (nos. 11 and 12). Spectra with PM of m/z 
308.1862 were revealed after threefold hydroxylation, represented by three O-demethyl 
cyclohexyl-hydroxy piperidine-dihydroxy metabolites (nos. 17-19). One product of the 
metabolites nos. 8-10 after oxidation and elimination of water could be observed with PM of 
m/z 288.1600 (no. 5).  
Concerning phase II metabolism, seven glucuronides were found (nos. 57-63 in Table 
3). These conjugates were identified by the PM shift of +176.0322 u. The fragment ions were 
identical to those of the underlying phase I metabolites. One of these glucuronides was 
postulated as O-demethyl aryl-hydroxy glucuronide (no. 58). The corresponding phase I 
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metabolite could not be detected, either due to low concentrations or insufficient conjugate 
cleavage during work-up procedure for this particular metabolite. The position in the aromatic 
ring system could be confirmed with performed LC-HR-MS/MS analysis, revealing a 
spectrum with an additional fragment ion of m/z 123.0440 (C7H7O2), representing a dihydroxy 
tropylium ion. 
 
3.2.2. 3-MeO-PCPy 
 
The parent compound spectrum (no. 31 in Table 2) showed a characteristic fragmentation 
pattern analogous to 3-MeO-PCP. The 3-methoxy-phenyl-cyclohexyl fragment was 
represented by the fragment ion of m/z 189.1279, but the corresponding pyrrolidine fragment 
at m/z 72.0813 was not detected. In analogy to 3-MeO-PCP, an unchanged 3-methoxy-phenyl-
cyclohexyl fragment was represented at m/z 189.1279 (nos. 37, 39, 44, and 51), after 
monohydroxylation at m/z 205.1229 (nos. 45, 46, and 52-55), after O-demethylation at m/z 
175.1123 (nos. 32, 33, 38, and 40), and after hydroxylation and O-demethylation at m/z 
191.1072 (nos. 34-36, 41-43, and 47-49). Although the pyrrolidine fragment was not 
detectable in the spectrum of the unchanged molecule, the corresponding fragments were 
observed in the spectra of the metabolites. When the pyrrolidine fragment was unchanged, 
fragment ions could be observed at m/z 72.0813 (no. 32), if monohydroxylated at m/z 88.0762 
(nos. 33 and 37), and if dihydroxylated at m/z 104.0712 (nos. 38, 39, 41-43, 45, and 46). Again, 
an aliphatic hydroxylation was proposed if water elimination was observed. These fragments 
were represented at m/z 187.1123 (205.1229 – 18.0100 u; nos. 45, 46, and 52-55), 173.0966 
(191.1072 – 18.0100 u; nos. 34-36, 41-43, and 47-50), and 70.0657 (88.0762 – 18.0100 u; 
nos. 33 and 37). 
A metabolite with PM of m/z 246.1858 revealed an O-demethyl metabolite (no. 32). 
One pyrrolidine-hydroxy metabolite was revealed by PM of m/z 276.1958 (no. 37), one 
pyrrolidine-dihydroxy metabolite by PM of m/z 292.1913 (no. 39), and two trihydroxy 
metabolite by PM of m/z 308.1862, both representing cyclohexyl-hydroxy pyrrolidine-
dihydroxy isomers (nos. 45 and 46). In contrast to 3-MeO-PCP, monohydroxylation at the 
cyclohexyl ring could not be detected being an intermediate to further steps. In accordance to 
3-MeO-PCP metabolism, aliphatic carboxy metabolites could be observed as carboxy 
metabolite (no. 44) with PM of m/z 306.2069, as four isomeric methyl artifacts of carboxy 
cyclohexyl-hydroxy metabolites (nos. 52-55) with PM of m/z 322.2018, as one methyl artifact 
of a carboxy cyclohexyl-dihydroxy metabolite (no. 56) with PM of m/z 338.1967, and as one 
carboxy alkyl-hydroxy metabolite (no. 51) with PM of m/z 322.2018. O-Demethylation and 
hydroxylation reactions could be observed for four O-demethyl hydroxy isomers with PM of 
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m/z 262.1807, whereby one isomer is postulated as the O-demethyl pyrrolidine-hydroxy 
metabolite (no. 33) and three isomers as O-demethyl cyclohexyl-hydroxy metabolites (nos. 
34-36). Moreover, after dihydroxylation, one O-demethyl pyrrolidine-dihydroxy metabolite 
with PM of m/z 278.1756 (no. 38) and after trihydroxylation three O-demethyl cyclohexyl-
hydroxy pyrrolidine-dihydroxy metabolites with PM of m/z 294.1705 (nos. 41-43) could be 
observed. Furthermore, one methyl artifact of an O-demethylated carboxy metabolite could be 
observed with PM of m/z 292.1949 (no. 40) and four isomers after additional cyclohexyl-
hydroxylation with PM of m/z 308.1862 (nos. 47-50). In analogy to 3-MeO-PCP metabolism 
studies, the methyl artifacts, postulated as methyl ester structures, were confirmed as 
described above.  
Concerning phase II metabolism, eight glucuronides were found, whereby 
corresponding phase I metabolites of five of them could not be detected (nos. 66-70 in Table 
4). The reason for the lack of corresponding phase I metabolites for the two aryl hydroxylated 
metabolites (nos. 66 and 67) were the same already described above. Again, the position of 
the hydroxy groups were confirmed by additional fragment ions of m/z 123.0440 (C7H7O2) in 
LC-HR-MS/MS. Furthermore, the other three glucuronides (nos. 68-70) showed keto groups 
at the pyrrolidine ring. The fact, that the corresponding phase I metabolites could not be 
detected after conjugate cleavage with subsequent SPE, non-basic structures could be 
proposed, which led to the suggestion of lactam ring formation following hydroxylation at the 
α-position and further oxidation.  
 
3.3. Proposed metabolic pathways 
 
The metabolic pathways, which could be proposed according to the identified metabolites, are 
given in Fig. 2 for 3-MeO-PCP and in Fig. 3 for 3-MeO-PCPy, respectively. Numbers 
correspond to those given in Tables 1-4. 
 
3.3.1. 3-MeO-PCP 
 
Hydroxylation steps could be detected at the cyclohexyl ring (no. 7 in Fig. 2), at the piperidine 
ring (no. 6), or at both rings forming two isomeric metabolites (nos. 14 and 15). The 
metabolite with monohydroxylated piperidine ring (no. 6) as well as both isomers of 
cyclohexyl-hydroxy piperidine-hydroxy (nos. 14 and 15) could further get hydroxylated at the 
piperidine ring to a piperidine-dihydroxy metabolite (no. 13) or to isomers of cyclohexyl-
hydroxy piperidine-dihydroxy metabolite, whereby only one isomer was detected (no. 24). If 
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hydroxylation of metabolite no. 6 took place at α-position to the amine, the resulting 
hemiaminal could perform a ring opening, and the formed aldehyde could be further oxidized 
to the corresponding carboxylic acid (no. 20). Further hydroxylation of this metabolite at the 
alkyl side chain (no. 30) or at the cyclohexyl ring to five isomeric structures (nos. 25-29) 
could be observed. O-Demethylation (no. 2) could be detected as another pathway, followed 
by hydroxylation at the cyclohexyl ring (no. 4), at the piperidine ring (no. 3), or at both rings, 
again into two isomeric metabolites (nos. 11 and 12). In analogy to the pathway without O-
demethylation, the metabolite with the monohydroxylated piperidine ring (no. 3) as well as 
both cyclohexyl-hydroxy piperidine-hydroxy isomers (nos. 11 and 12) could further get 
hydroxylated at the piperidine ring to three isomeric piperidine-dihydroxy metabolites (nos. 8-
10) or to three isomeric cyclohexyl-hydroxy piperidine-dihydroxy metabolites (nos. 17-19). 
Metabolite no. 5 could be explained as a product of one of the metabolites nos. 17-19 after 
oxidation of one hydroxy group and elimination of water. If hydroxylation of metabolite no. 3 
led to a hemiaminal, one ring opened carboxy metabolite (no. 16) and after further 
hydroxylation at the cyclohexyl ring three isomers (nos. 21-23) could be detected. 
Glucuronidation could be observed for metabolites nos. 6 (to 61), 2 (to 57), 3 (to 59 or 
60), 11 or 12 (to 63), and 8-10 (to 62). For the glucuronide no. 58, the corresponding 
precursor should be an aryl-hydroxy of metabolite no. 2, which could not be detected possibly 
for reasons already described above. 
 
3.3.2. 3-MeO-PCPy 
 
The metabolic pathways were similar to those of 3-MeO-PCP. Hydroxylation could be 
detected at the pyrrolidine ring after monohydroxylation (no. 37 in Fig. 3) and 
dihydroxylation (no. 39). At the cyclohexyl ring, monohydroxylation was not observed but 
two isomers in combination with a dihydroxy pyrrolidine ring (nos. 45 and 46). Again, after 
ring opening, one carboxylic acid metabolite (no. 44), one after further hydroxylation at the 
alkyl side chain (no. 51), four cyclohexyl-monohydroxy isomers (nos. 52-55), and one 
cyclohexyl-dihydroxy isomer (no. 56) were detected. O-Demethylation (no. 32) followed by 
hydroxylation at the piperidine ring led to one monohydroxy (no. 33) and one dihydroxy 
isomer (no. 38). At the cyclohexyl ring, three monohydroxy (nos. 34-36), but no dihydroxy 
isomers were detected. Combinations only occurred with dihydroxy pyrrolidine ring, again 
resulting in three isomeric structures (nos. 41-43) fitting with the three precursor isomers nos. 
34-36. O-Demethylation in combination with ring opening led to metabolite no. 40 and to the 
three isomers nos. 47-50 after further cyclohexyl-monohydroxylation. 
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Glucuronidation could be observed for metabolites nos. 45 or 46 (to 71), 32 (to 64), and 
33 (to 65). The precursor of no. 68 was a pyrrolidine-monohydroxy metabolite in α-position 
(no. 37) followed by oxidation to the lactams, those of nos. 69 and 70 after further 
cyclohexyl-hydroxylation. Metabolite no. 66 resulted by aryl-hydroxylation of the O-
demethyl metabolite no. 32 followed by glucuronidation. Metabolite no. 67 resulted from 
metabolite no. 66 after additional lactam formation. 
 
3.4. Microsomal incubations and initial CYP activity screening 
 
Incubations with pHLM were carried out for comparison of the formed rat phase I metabolites 
with those of humans. For 3-MeO-PCP, the metabolites nos. 2, 3, 4, 7, and 13 from Table 1, 
for 3-MeO-PCPy, the metabolites nos. 32 and 39 from Table 2 were detected after pHLM 
incubation. Essentially, O-demethylation and hydroxylation at the pyrrolidine and/or the 
cyclohexyl ring were observed for both species. However, ring opening steps could not be 
detected in pHLM, what could either be explained by low formation rates or by 
interindividual isomeric variability that could lead to the absence of hydroxylation products in 
the α-position in humans, and thus, absence of detectable carboxy metabolites. 
To test the involvement of single CYP enzymes in the initial metabolic steps, the 
proposed metabolites were detected after incubations with the ten most important human 
hepatic CYP enzymes. The involvement of the corresponding CYPs is shown in Table 5 for 
3-MeO-PCP and for 3-MeO-PCPy. The relative involvement of individual CYPs was defined 
in relation to the highest peak abundances during precursor ion monitoring of the formed 
metabolites. CYPs forming the relative highest peak abundances are given with “++” and all 
others with “+”. 
For 3-MeO-PCP, CYP 2B6 was involved in the formation of hydroxylation at the 
cyclohexyl ring as well as at the piperidine ring. O-Demethylation was performed by CYP 
2C19, 2B6, and CYP 2D6. Regarding 3-MeO-PCPy, hydroxylation at the pyrrolidine ring was 
again catalyzed by CYP 2B6. However, cyclohexyl-hydroxylation was not detected. 
Concerning O-demethylation, CYP 2C9, 2B6, and CYP 2D6 were involved. As most 
involved enzymes were polymorphically expressed, pharmacogenomic variations might 
occur, but clinical data are needed for further studies.  
 
3.5. Toxicological detection by GC-MS, LC-MSn, and LC-HR-MS/MS 
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To test for toxicological detectability after common users’ doses of approximately 10 mg 
(https://www.erowid.org, http://bluelight.org), rat urines were screened after administration of 
compound doses scaled by the dose-by-factor approach of Sharma and McNeill [13] via GC-
MS, LC-MSn, and LC-HR-MS/MS SUSA. The detected targets for both compounds are given 
in Table 6-8. 
For 3-MeO-PCP, detection was possible via the parent compound (no. 1) and 
metabolites nos. 2 and 3 by GC-MS, via metabolites nos. 8, 13, 57, 58, and 61 by LC-MSn, 
and nos. 2, 3, 8, 13, 24, 57, 58, 59, and 61 by LC-HR-MS/MS. Administration of 3-MeO-
PCPy could be monitored via the metabolites no. 32 by GC-MS, nos. 32, 38, 39, 64, and 67 
by LC-MSn, and nos. 32, 38, 39, 45, 64, 66, and 67 by LC-HR-MS/MS. The reason why not 
all types of metabolites were found for both drugs could be explained by different formation 
rates, influence of ion suppression, chromatographic and/or ionization properties. The risk of 
overlooking a drug consumption caused by ion suppression could be minimized by screening 
for several targets e.g. metabolites. 
For general performance of the SUSAs, increasing concentrations of the parent drugs 
were analyzed although they were not the main targets chosen for urine analysis. The limits of 
detection (LOD) were determined at a signal-to-noise ratio of 3. In GC-MS, LC-MSn, and LC-
HR-MS/MS, the LODs were 5, 10, and 0.1 ng/mL for 3-MeO-PCP and 10, 10, and 0.1 ng/mL 
for 3-MeO-PCPy, respectively. 
 
4. CONCLUSIONS 
 
The PCP analogues 3-MeO-PCP and 3-MeO-PCPy were extensively metabolized in rats via 
aliphatic and aromatic hydroxylation, carboxylation after ring opening, O-demethylation, and 
glucuronidation. The initial steps could be confirmed by detection of the corresponding 
metabolites in pHLM incubations. The CYP enzymes involved in the metabolism of both 
compounds were CYP 2B6 and CYP 2D6. In addition, CYP 2C19 was involved in 3-MeO-
PCP O-demethylation and piperidine-hydroxylation whereas CYP 2C9 in 3-MeO-PCPy O-
demethylation. As only polymorphically expressed enzymes were involved, 
pharmacogenomic variations might occur, but clinical data are needed to confirm the 
relevance. Detectability studies showed that all tested SUSAs were able to monitor 
consumptions of both drugs considering that metabolites were the main targets. 
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Table 1: 3-MeO-PCP and its phase I metabolites detected in rat urine by LC-HR-MSn with 
protonated precursor mass (PM), characteristic fragment ions (FI), calculated exact masses, 
proposed elemental composition, mass error, relative intensity, and retention times 
 
No. Metabolite Measured 
accurate 
mass (m/z) 
Calculated 
exact mass 
(m/z) 
Error 
(ppm) 
Elemental 
composition 
Relative 
intensity 
(%) 
RT 
(min) 
1 3-MeO-PCP 10.6 
  274.2166 274.2171 -1.82 C18H28NO 100  
  86.0963 86.0970 -8.13 C5H12N 100  
  189.1277 189.1279 -1.06 C13H17O 40  
2 3-MeO-PCP-M (O-demethyl-) 7.3 
  260.2006 260.2014 -3.07 C17H26NO 100  
  86.0964 86.0970 -6.97 C5H12N 100  
  175.1122 175.1123 -0.57 C12H15O 26  
3 3-MeO-PCP-M (O-demethyl-piperidine-HO-) 6.1 
  276.1955 276.1964 -3.26 C17H26NO2 100  
  84.0808 84.0813 -5.95 C5H10N 8  
  102.0914 102.0919 -4.90 C5H12NO 100  
  175.1122 175.1123 -0.57 C12H15O 30  
4 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-) 5.1 
  276.1959 276.1964 -1.81 C17H26NO2 100  
  86.0964 86.0970 -6.97 C5H12N 100  
  173.0965 173.0966 -0.58 C12H13O 30  
  191.1071 191.1072 -0.52 C12H15O2 6  
5 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-dehydro-oxo-piperidine-) 5.7 
  288.1598 288.1600 -0.69 C17H22NO3 100  
  80.0497 80.0500 -3.75 C5H6N 5  
  98.0601 98.0606 -5.10 C5H8NO 100  
  173.0965 173.0966 -0.58 C12H13O 6  
  191.1073 191.1072 0.52 C12H15O2 1  
6 3-MeO-PCP-M (piperidine-HO-) 8.9 
  290.2115 290.2120 -1.72 C18H28NO2 28  
  84.0808 84.0813 -5.95 C5H10N 1  
  102.0914 102.0919 -4.90 C5H12NO 18  
  189.1278 189.1279 -0.53 C13H17O 8  
7 3-MeO-PCP-M (cyclohexyl-HO-) 7.6 
  290.2177 290.2170 2.41 C18H28NO2 60  
  86.0964 86.0970 -6.97 C5H12N 100  
  187.1122 187.1123 -0.53 C13H15O 52  
  205.1227 205.1229 -0.98 C13H17O2 14  
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8 3-MeO-PCP-M (O-demethyl-piperidine-di-HO-) isomer 1 7.3 
  292.1906 292.1913 -2.40 C17H26NO3 30  
  101.0598 101.0603 -4.95 C5H9O2 18  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  175.1121 175.1123 -1.14 C12H15O 20  
9 3-MeO-PCP-M (O-demethyl-piperidine-di-HO-) isomer 2 8.1 
  292.1911 292.1913 -0.68 C17H26NO3 100  
  101.0598 101.0603 -4.95 C5H9O2 38  
  118.0865 118.0868 -2.54 C5H12NO2 100  
  175.1121 175.1123 -1.14 C12H15O 28  
10 3-MeO-PCP-M (O-demethyl-piperidine-di-HO-) isomer 3 9.2 
  292.1912 292.1913 -0.34 C17H26NO3 26  
  101.0600 101.0603 -2.97 C5H9O2 1  
  118.0865 118.0868 -2.54 C5H12NO2 1  
  175.1119 175.1123 -2.28 C12H15O 1  
11 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-HO-) isomer 1 2.4 
  292.1909 292.1913 -1.37 C17H26NO3 100  
  84.0807 84.0813 -7.14 C5H10N 1  
  102.0914 102.0919 -4.90 C5H12NO 100  
  173.0965 173.0966 -0.58 C12H13O 14  
  191.1071 191.1072 -0.52 C12H15O2 2  
12 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-HO-) isomer 2 4.1 
  292.1909 292.1913 -1.37 C17H26NO3 78  
  84.0808 84.0813 -5.95 C5H10N 1  
  102.0913 102.0919 -5.88 C5H12NO 100  
  173.0963 173.0966 -1.73 C12H13O 20  
  191.1070 191.1072 -1.05 C12H15O2 3  
13 3-MeO-PCP-M (piperidine-di-HO-) 10.2 
  306.2064 306.2069 -1.63 C18H28NO3 50  
  101.0597 101.0603 -5.94 C5H9O2 16  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  189.1276 189.1279 -1.59 C13H17O 56  
14 3-MeO-PCP-M (cyclohexyl-HO-piperidine-HO-) isomer 1 4.2 
  306.2065 306.2069 -1.31 C18H28NO3 100  
  84.0806 84.0813 -8.33 C5H10N 1  
  102.0913 102.0919 -5.88 C5H12NO 100  
  187.1120 187.1123 -1.60 C13H15O 24  
  205.1226 205.1229 -1.46 C13H17O2 8  
15 3-MeO-PCP-M (cyclohexyl-HO-piperidine-HO-) isomer 2 5.8 
  306.2065 306.2069 -1.31 C18H28NO3 38  
  102.0914 102.0919 -4.90 C5H12NO 100  
  187.1122 187.1123 -0.53 C13H15O 30  
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  205.1228 205.1229 -0.49 C13H17O2 10  
16 3-MeO-PCP-M (O-demethyl-carboxy-) methyl artifact  8.7 
  306.2062 306.2069 -2.29 C18H28NO3 100  
  115.0756 115.0759 -2.61 C6H11O2 30  
  132.1022 132.1025 -2.27 C6H14NO2 100  
  175.1122 175.1123 -0.57 C12H15O 18  
17 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-di-HO-) isomer 1 4.9 
  308.1856 308.1862 -1.95 C17H26NO4 100  
  101.0598 101.0603 -4.95 C5H9O2 1  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  173.0965 173.0966 -0.58 C12H13O 14  
  191.1070 191.1072 -1.05 C12H15O2 2  
18 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-di-HO-) isomer 2 5.1 
  308.1858 308.1862 -1.30 C17H26NO4 20  
  101.0598 101.0603 -4.95 C5H9O2 1  
  118.0864 118.0868 -3.39 C5H12NO2 4  
  191.1068 191.1072 -2.09 C12H15O2 1  
19 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-di-HO-) isomer 3 5.5 
  308.1857 308.1862 -1.62 C17H26NO4 78  
  101.0597 101.0603 -5.94 C5H9O2 1  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  173.0964 173.0966 -1.16 C12H13O 20  
  191.1070 191.1072 -1.05 C12H15O2 3  
20 3-MeO-PCP-M (carboxy-) methyl artifact 11.7 
  320.2216 320.2226 -3.12 C19H39NO3 100  
  115.0756 115.0759 -2.61 C6H11O2 30  
  132.1022 132.1025 -2.27 C6H14NO2 100  
  189.1278 189.1279 -0.53 C13H17O 40  
21 3-MeO-PCP-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 1  5.2 
  322.2016 322.2018 -0.62 C18H28NO4 100  
  115.0755 115.0759 -3.48 C6H11O2 28  
  132.1021 132.1025 -3.03 C6H14NO2 100  
  173.0963 173.0966 -1.73 C12H13O 6  
  191.1069 191.1072 -1.57 C12H15O2 1  
22 3-MeO-PCP-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 2 5.8 
  322.2012 322.2018 -1.86 C18H28NO4 100  
  115.0755 115.0759 -3.48 C6H11O2 26  
  132.1021 132.1025 -3.03 C6H14NO2 100  
  173.0964 173.0966 -1.16 C12H13O 14  
  191.1070 191.1072 -1.05 C12H15O2 2  
23 3-MeO-PCP-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 3 6.2 
  322.2011 322.2018 -2.17 C18H28NO4 58  
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  115.0755 115.0759 -3.48 C6H11O2 30  
  132.1022 132.1025 -2.27 C6H14NO2 100  
  173.0965 173.0966 -0.58 C12H13O 20  
  191.1071 191.1072 -0.52 C12H15O2 2  
24 3-MeO-PCP-M (cyclohexyl-HO-piperidine-di-HO-) 3.8 
  322.2016 322.2018 -0.62 C18H28NO4 100  
  100.0758 100.0762 -4.00 C5H10NO 1  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  187.1120 187.1123 -1.60 C13H15O 24  
  205.1226 205.1229 -1.46 C13H17O2 8  
25 3-MeO-PCP-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 1  7.2 
  336.2175 336.2175 0.00 C19H30NO4 36  
  115.0756 115.0759 -2.61 C6H11O2 34  
  132.1023 132.1025 -1.51 C6H14NO2 100  
  187.1124 187.1123 0.53 C13H15O 20  
  205.1229 205.1229 0.00 C13H17O2 4  
26 3-MeO-PCP-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 2  8.0 
  336.2173 336.2175 -0.59 C19H30NO4 52  
  115.0755 115.0759 -3.48 C6H11O2 30  
  132.1021 132.1025 -3.03 C6H14NO2 100  
  187.1121 187.1123 -1.07 C13H17O 24  
  205.1226 205.1229 -1.46 C13H17O2 8  
27 3-MeO-PCP-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 3  8.5 
  336.2172 336.2175 -0.89 C19H30NO4 80  
  115.0756 115.0759 -2.61 C6H11O2 10  
  132.1022 132.1025 -2.27 C6H14NO2 34  
  187.1122 187.1123 -0.53 C13H15O 20  
  205.1228 205.1229 -0.49 C13H17O2 4  
28 3-MeO-PCP-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 4  8.9 
  336.2172 336.2175 -0.89 C19H30NO4 24  
  115.0755 115.0759 -3.48 C6H11O2 32  
  132.1022 132.1025 -2.27 C6H14NO2 100  
  187.1122 187.1123 -0.53 C13H15O 18  
  205.1227 205.1229 -0.98 C13H17O2 2  
29 3-MeO-PCP-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 5  9.1 
  336.2171 336.2175 -1.19 C19H30NO4 45  
  115.0755 115.0759 -3.48 C6H11O2 20  
  132.1021 132.1025 -3.03 C6H14NO2 60  
  187.1122 187.1123 -0.53 C13H15O 8  
  205.1226 205.1229 -1.46 C13H17O2 100  
30 3-MeO-PCP-M (carboxy-alkyl-HO-) 10.5 
  336.2172 336.2175 -0.89 C19H30NO4 50  
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  99.0439 99.0446 -7.07 C5H7O2 1  
  131.0704 131.0708 -3.05 C6H11O3 6  
  148.0970 148.0974 -2.70 C6H14NO3 100  
  189.1277 189.1279 -1.06 C13H17O 28  
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Table 2: 3-MeO-PCPy and its phase I metabolites detected in rat urine by LC-HR-MSn with 
protonated precursor mass (PM), characteristic fragment ions (FI), calculated exact masses, 
proposed elemental composition, mass error, relative intensity, and retention times 
 
No. Metabolite Measured 
accurate 
mass (m/z) 
Calculated 
exact mass 
(m/z) 
Error 
(ppm) 
Elemental 
composition 
Relative 
intensity 
(%) 
RT 
(min) 
31 3-MeO-PCPy 10.0 
  260.2010 260.2014 -1.54 C17H26NO 42  
  189.1276 189.1279 -1.59 C13H17O 100  
32 3-MeO-PCPy-M (O-demethyl-) 6.6 
  246.1850 246.1858 -3.25 C16H24NO 100  
  72.0807 72.0813 -8.32 C4H10N 68  
  175.1121 175.1123 -1.14 C12H15O 100  
33 3-MeO-PCPy-M (O-demethyl-pyrrolidine-HO-) 6.1 
  262.1802 262.1807 -1.91 C16H24NO2 100  
  70.0651 70.0657 -8.56 C4H8N 1  
  88.0756 88.0762 -6.81 C4H10NO 100  
  175.1120 175.1123 -1.71 C12H15O 24  
34 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-) isomer 1 4.4 
  262.1801 262.1807 -2.29 C16H24NO2 70  
  173.0963 173.0966 -1.73 C12H13O 100  
  191.1069 191.1072 -1.57 C12H15O2 18  
35 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-) isomer 2 4.6 
  262.1801 262.1807 -2.29 C16H24NO2 100  
  173.0963 173.0966 -1.73 C12H13O 100  
  191.1062 191.1072 -5.23 C12H15O2 14  
36 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-) isomer 3 5.6 
  262.1806 262.1807 -0.38 C16H24NO2 64  
  173.0966 173.0966 0.00 C12H13O 4  
  191.1070 191.1072 -1.05 C12H15O2 20  
37 3-MeO-PCPy-M (pyrrolidine-HO-) 8.8 
  276.1958 276.1964 -2.17 C17H26NO2 60  
  70.0659 70.0657 2.85 C4H8N 2  
  88.0756 88.0762 -6.81 C4H10NO 100  
  189.1277 189.1279 -1.06 C13H17O 70  
38 3-MeO-PCPy-M (O-demethyl-pyrrolidine-di-HO-) 6.5 
  278.1754 278.1756 -0.72 C16H24NO3 84  
  87.0440 87.0446 -6.89 C4H7O2 14  
  104.0706 104.0712 -5.77 C4H10NO2 100  
  175.1120 175.1123 -1.71 C12H15O 50  
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39 3-MeO-PCPy-M (pyrrolidine-di-HO-) 9.5 
  292.1905 292.1913 -2.74 C17H26NO3 18  
  87.0440 87.0446 -6.89 C4H7O2 10  
  104.0707 104.0712 -4.80 C4H10NO2 94  
  189.1277 189.1279 -1.06 C13H17O 100  
40 3-MeO-PCPy-M (O-demethyl-carboxy-) methyl artifact 8.0 
  292.1907 292.1913 -2.05 C17H26NO3 100  
  101.0598 101.0603 -4.95 C5H9O2 38  
  118.0865 118,0868 -2.54 C5H12NO2 100  
  175.1122 175.1123 -0.57 C12H15O 30  
41 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-pyrrolidine-di-HO-) isomer 1 3.0 
  294.1710 294.1705 1.70 C16H24NO4 22  
  87.0440 87.0446 -6.89 C4H7O2 10  
  104.0706 104.0712 -5.77 C4H10NO2 100  
  173.0963 173.0966 -1.73 C12H13O 20  
  191.1071 191.1072 -0.52 C12H15O2 4  
42 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-pyrrolidine-di-HO-) isomer 2 4.0 
  294.1703 294.1705 -0.68 C16H24NO4 94  
  87.0440 87.0446 -6.89 C4H7O2 10  
  104.0706 104.0712 -5.77 C4H10NO2 100  
  173.0964 173.0966 -1.16 C12H13O 44  
  191.1069 191.1072 -1.57 C12H15O2 12  
43 3-MeO-PCPy-M (O-demethyl-cyclohexyl-HO-pyrrolidine-di-HO-) isomer 3 4.4 
  294.1701 294.1705 -1.36 C16H24NO4 92  
  87.0441 87.0446 -5.74 C4H7O2 12  
  104.0707 104.0712 -4.80 C4H10NO2 100  
  173.0965 173.0966 -0.58 C12H13O 30  
  191.1072 191.1072 0.00 C12H15O2 6  
44 3-MeO-PCPy-M (carboxy-) 11.0 
  306.2058 306.2069 -3.59 C18H28NO3 100  
  101.0597 101.0603 -5.94 C5H9O2 40  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  189.1277 189.1279 -1.06 C13H17O 70  
45 3-MeO-PCPy-M (cyclohexyl-HO-pyrrolidine-di-HO-) isomer 1 4.7 
  308.1856 308.1862 -1,95 C17H26NO4 20  
  86.0440 87.0446 -6,89 C4H7O2 6  
  104.0707 104.0712 -4,80 C4H10NO2 100  
  187.1121 187.1123 -1,07 C13H15O 42  
  205.1227 205.1229 -0,98 C13H17O2 14  
46 3-MeO-PCPy-M (cyclohexyl-HO-pyrrolidine-di-HO-) isomer 2 6.3 
  308.1858 308.1862 -1.30 C17H26NO4 82  
  87.0441 87.0446 -5.74 C4H7O2 2  
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  104.0707 104.0712 -4.80 C4H10NO2 44  
  187.1121 187.1123 -1.07 C13H15O 20  
  205.1227 205.1229 -0.98 C13H17O2 6  
47 3-MeO-PCPy-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 1 5.0 
  308.1855 308.1862 -2.27 C17H26NO4 100  
  101.0598 101.0603 -4.95 C5H9O2 30  
  118.0865 118.0868 -2.54 C5H12NO2 100  
  173.0966 173.0966 0.00 C12H13O 20  
  191.1072 191.1072 0.00 C12H15O2 4  
48 3-MeO-PCPy-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 2 5.4 
  308.1852 308.1862 -3.24 C17H26NO4 100  
  101.0597 101.0603 -5.94 C5H9O2 40  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  173.0964 173.0966 -1.16 C12H13O 18  
  191.1070 191.1072 -1.05 C12H15O2 2  
49 3-MeO-PCPy-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 3 6.3 
  308.1857 308.1862 -1.62 C17H26NO4 88  
  87.0440 87.0446 -6.89 C4H7O2 1  
  101.0598 101.0603 -4.95 C5H9O2 38  
  118.0864 118.0868 -3.39 C5H12NO2 100  
  173.0963 173.0966 -1.73 C12H13O 6  
  191.1070 191.1072 -1.05 C12H15O2 16  
50 3-MeO-PCPy-M (O-demethyl-carboxy-cyclohexyl-HO-) methyl artifact isomer 4 10.2 
  308.1859 308.1862 -0.97 C17H26NO4 34  
  101.0599 101.0603 -3.96 C5H9O2 8  
  118.0864 118.0868 -3.39 C5H12NO2 24  
  173.0965 173.0966 -0.58 C12H13O 4  
51 3-MeO-PCPy-M (carboxy-alkyl-HO-) methyl artifact 9.7 
  322.2015 322.2018 -0.93 C18H28NO4 80  
  102.0553 102.0555 -1.96 C4H8NO2 1  
  117.0548 117.0551 -2.56 C5H9O3 26  
  134.0814 134.0817 -2.24 C5H12NO3 100  
  189.1278 189.1279 -0.53 C13H17O 30  
52 3-MeO-PCPy-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 1 6.1 
  322.2012 322.2018 -1.86 C18H28NO4 34  
  101.0597 101.0603 -5.94 C5H9O2 30  
  118.0863 118.0868 -4.23 C5H12NO2 100  
  187.1119 187.1123 -2.14 C13H15O 20  
  205.1225 205.1229 -1.95 C13H17O2 6  
53 3-MeO-PCPy-M carboxy-cyclohexyl-HO-) methyl artifact isomer 2 7.1 
  322.2014 322.2018 -1.24 C17H28NO4 32  
  101.0597 101.0603 -5.94 C5H9O2 30  
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  118.0863 118.0868 -4.23 C5H12NO2 100  
  187.1119 187.1123 -2.14 C13H15O 48  
  205.1225 205.1229 -1.95 C13H17O2 12  
54 3-MeO-PCPy-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 3 7.8 
  322.2016 322.2018 -0.62 C18H28NO4 100  
  101.0598 101.0603 -4.95 C5H9O2 32  
  118.0865 118.0868 -2.54 C5H12NO2 100  
  187.1122 187.1123 -0.53 C13H15O 30  
  205.1228 205.1229 -0.49 C13H17O2 6  
55 3-MeO-PCPy-M (carboxy-cyclohexyl-HO-) methyl artifact isomer 4 8.3 
  322.2016 322.2018 -0.62 C18H28NO4 100  
  101.0598 101.0603 -4.95 C5H9O2 10  
  118.0865 118.0868 -2.54 C5H12NO2 30  
  187.1120 187.1123 -1.60 C13H15O 8  
  205.1227 205.1229 -0.98 C13H17O2 100  
56 3-MeO-PCPy-M (carboxy-cyclohexyl-di-HO-) methyl artifact 5.4 
  338.1958 338.1967 -2.66 C18H28NO5 4  
  101.0597 101.0603 -5.94 C5H9O2 24  
  118.0863 118.0868 -4.23 C5H12NO2 100  
  203.1069 203.1072 -1.48 C13H15O2 40  
  221.1174 221.1178 -1.81 C13H17O3 70  
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Table 3: 3-MeO-PCP and its phase II metabolites detected in rat urine by LC-HR-MSn with 
protonated precursor mass (PM), characteristic fragment ions (FI), calculated exact masses, 
proposed elemental composition, mass error, relative intensity, and retention times 
 
No. Metabolite Measured 
accurate 
mass (m/z) 
Calculated 
exact mass 
(m/z) 
Error 
(ppm) 
Elemental 
composition 
Relative 
intensity 
(%) 
RT 
(min) 
57 3-MeO-PCP-M (O-demethyl-) glucuronide 5.3 
  436.2320 436.2335 -3.44 C23H34NO7 100  
  175.1117 175.1123 -3.43 C12H15O 100  
  351.1436 351.1444 -2.28 C18H23O7 3  
58 3-MeO-PCP-M (O-demethyl-aryl-HO-) glucuronide 4.6 
  452.2272 452.2284 -2.65 C23H34NO8 100  
  175.1117 175.1123 -3.43 C12H15O 100  
  191.1066 191.1072 -3.14 C12H15O2 30  
  367.1386 367.1393 -1.91 C18H23O8 60  
59 3-MeO-PCP-M (O-demethyl-piperidine-HO-) glucuronide isomer 1 5.7 
  452.2272 452.2284 -2.65 C23H24NO8 100  
  175.1119 175.1123 -2.28 C12H15O 3  
  278.1235 278.1240 -1.80 C11H20NO7 100  
60 3-MeO-PCP-M (O-demethyl-piperidine-HO-) glucuronide isomer 2 5.9 
  452.2275 452.2284 -1.99 C23H34NO8 100  
  175.1118 175.1123 -2.86 C12H15O 3  
  278.1234 278.1240 -2.16 C11H20NO7 100  
61 3-MeO-PCP-M (piperidine-HO-) glucuronide 8.1 
  466.2432 466.2441 -1.93 C24H36NO8 100  
  189.1275 189.1279 -2.11 C13H17O 6  
  278.1235 278.1240 -1.80 C11H20NO7 100  
62 3-MeO-PCP-M (O-demethyl-piperidine-di-HO-) glucuronide 5.5 
  468.2226 468.2234 -1.71 C23H34NO9 10  
  175.1117 175.1123 -3.43 C12H15O 2  
  351.1440 351.1444 -1.14 C18H23O7 100  
63 3-MeO-PCP-M (O-demethyl-cyclohexyl-HO-piperidine-HO-) glucuronide 4.3 
  468.2263 468.2234 6.19 C23H34NO9 14  
  191.1067 191.1072 -2.62 C12H15O2 90  
  367.1389 367.1393 -1.09 C18H23O8 100  
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Table 4: 3-MeO-PCPy and its phase II metabolites detected in rat urine by LC-HR-MSn with 
protonated precursor mass (PM), characteristic fragment ions (FI), calculated exact masses, 
proposed elemental composition, mass error, relative intensity, and retention times 
 
No. Metabolite Measured 
accurate 
mass (m/z) 
Calculated 
exact mass 
(m/z) 
Error 
(ppm) 
Elemental 
composition 
Relative 
intensity 
(%) 
RT 
(min) 
64 3-MeO-PCPy-M (O-demethyl-) glucuronide 5.1 
  422.2169 422.2179 -2.37 C22H32NO7 100  
  175.1118 175.1123 -2.86 C12H15O 100  
  351.1411 351.1444 -9.40 C18H23O7 1  
65 3-MeO-PCPy-M (O-demethyl-pyrrolidine-HO-) glucuronide 5.8 
  438.2121 438.2128 -1.60 C22H32NO8 60  
  175.1118 175.1123 -2.86 C12H15O 1  
  264.1078 264.1083 -1.89 C10H18NO7 100  
66 3-MeO-PCPy-M (O-demethyl-aryl-HO-) glucuronide 4.5 
  438.2119 438.2128 -2.05 C22H32NO8 100  
  191.1067 191.1072 -2.62 C12H15O2 50  
  367.1388 367.1393 -1.36 C18H23O8 100  
67 3-MeO-PCPy-M (O-demethyl-aryl-HO-pyrrolidine-2-oxo-) glucuronide 10.1 
  452.1915 452.1920 -1.11 C22H30NO9 30  
  191.1067 191.1072 -2.62 C12H15O2 100  
  367.1387 367.1393 -1.63 C18H23O8 72  
68 3-MeO-PCPy-M (cyclohexyl-HO-pyrrolidine-2-oxo-) glucuronide 10.8 
  466.2072 466.2077 -1.07 C23H32NO9 50  
  205.1222 205.1229 -3.41 C13H17O2 100  
  381.1543 381.1549 -1.57 C19H25O8 12  
69 3-MeO-PCPy-M (cyclohexyl-di-HO-pyrrolidine-2-oxo-) glucuronide isomer 1 4.6 
  482.2020 482.2026 -1.24 C23H32NO10 10  
  203.1068 203.1072 -1.97 C13H15O2 40  
  221.1173 221.1178 -2.26 C13H17O3 100  
  397.1492 397.1499 -1.76 C19H25O9 8  
70 3-MeO-PCPy-M (cyclohexyl-di-HO-pyrrolidine-2-oxo-) glucuronide isomer 2 5.2 
  482.2020 482.2026 -1.24 C23H32NO10 14  
  203.1065 203.1072 -3.45 C13H15O2 44  
  221.1170 221.1178 -3.62 C13H17O3 100  
  397.1482 397.1499 -4.28 C19H25O9 4  
71 3-MeO-PCPy-M (cyclohexyl-HO-pyrrolidine-di-HO-) glucuronide 8.0 
  484.2178 484.2183 -1.03 C23H34NO10 60  
  205.1224 205.1229 -2.44 C13H17O2 100  
  381.1545 381.1549 -1.05 C19H25O8 20  
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Table 5: General involvement of human CYP isoenzymes in initial metabolic steps of 3-
MeO-PCP and 3-MeO-PCPy 
 
 CYP 
1A2 
CYP 
2A6 
CYP 
2B6 
CYP 
2C8 
CYP 
2C9 
CYP 
2C19 
CYP 
2D6 
CYP 
2E1 
CYP 
3A4 
CYP 
3A5 
3-MeO-PCP           
O-Demethylation   +   ++ +    
Piperidine-hydroxylation   ++   +     
Cyclohexyl-hydroxylation   ++        
3-MeO-PCPy            
O-Demethylation   +  +  ++    
Pyrrolidine-hydroxylation   ++        
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Table 6: Proposed targets for GC-MS SUSA monitoring 3-MeO-PCP or 3-MeO-PCPy, with 
molecular masses, most abundant fragment ions, their relative intensities, and retention 
indices (RI) according to Kovats [16]. The numbers correspond to those in Fig 2 and 3. 
 
No. Target for SUSA Molecular 
mass (u) 
GC-MS fragment ions (m/z), and 
relative intensity (%) 
RI 
2 3-MeO-PCP 273 273 (40), 230 (100), 161 (52), 121 
(41) 
2120 
2 3-MeO-PCP-M (O-demethyl-) AC 301 84 (18), 166 (21), 244 (16), 258 
(100), 301 (28) 
2210 
3 3-MeO-PCP-M (O-demethyl-piperidine-HO-) 
2 AC 
359 164 (16), 258 (21), 300 (100), 316 
(12), 359 (15) 
2510 
32 3-MeO-PCPy-M (O-demethyl-) AC 287 70 (38), 107 (60), 152 (38), 244 
(100), 287 (22) 
2160 
 
 
Accepted (uncorrected) for publication in Current Neuropharmacology (03 October 2016) 
	
33	
Table 7: Proposed targets for LC-MSn SUSA monitoring 3-MeO-PCP or 3-MeO-PCPy, with 
protonated precursor ions, characteristic MS2 and MS3 fragment ions, and retention times 
(RT). The numbers correspond to those in Fig 2 and 3. 
 
No. Target for SUSA Precursor 
ions (m/z) 
MS2 fragment ions 
(m/z), and relative 
intensity (%) 
MS3 fragment ions 
(m/z), and relative 
intensity (%) 
RT 
(min) 
8 3-MeO-PCP-M (O-demethyl-piperidine-di-
HO-) 
292 101 (20), 118, 
(100), 175 (25) 
175: 81 (10), 107 
(100) 
8.6 
13 3-MeO-PCP-M (piperidine-di-HO-) 306 101 (20), 118 
(100), 189 (56) 
189: 81 (20), 121 
(100) 
11.6 
57 3-MeO-PCP-M (O-demethyl-) glucuronide 436 175 (100), 315 
(70), 391 (10) 
175: 81 (20), 107 
(100) 
5.5 
58 3-MeO-PCP-M (O-demethyl-aryl-HO-) 
glucuronide 
452 175 (20), 191 (90), 
367 (100) 
191: 81 (6), 123 
(100) 
4.6 
61 3-MeO-PCP-M (piperidine-HO-) 
glucuronide 
466 189 (6), 278 (100) 278: 84 (53), 102 
(90), 242 (100) 
9.0 
32 3-MeO-PCPy-M (O-demethyl-) 246 72 (100), 175 (60) 175: 81 (15), 107 
(100) 
8.2 
38 3-MeO-PCPy-M (O-demethyl-pyrrolidine-
di-HO-) 
278 87 (14), 104 (100), 
175 (50), 232 (30) 
175: 81 (20), 107 
(100) 
7.3 
39 3-MeO-PCPy-M (pyrrolidine-di-HO-) 292 87 (10), 104 (94), 
189 (100) 
189: 81 (20), 121 
(100) 
10.9 
64 3-MeO-PCPy-M (O-demethyl-) glucuronide 422 175 (100), 315 (1) 175: 81 (30), 107 
(100) 
4.9 
67 3-MeO-PCPy-M (O-demethyl-aryl-HO-
pyrrolidine-2-oxo-) glucuronide 
452 191 (70), 367 (100) 191: 81 (6), 123 
(100) 
10.6 
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Table 8: Proposed targets for LC-HR-MS/MS SUSA monitoring 3-MeO-PCP or 3-MeO-
PCPy, with protonated precursor ions, characteristic MS2 fragment ions, and retention times 
(RT). The numbers correspond to those in Figs. 2 and 3. 
 
No. Target for SUSA Precursor 
ions (m/z) 
MS2 fragment ions (m/z) and relative 
intensity (%) 
RT 
(min) 
2 3-MeO-PCP-M (O-demethyl-) 260.2014 81.0701 (15), 86.0966 (100), 
107.0490 (73), 175.1111 (37), 
260.2001 (4) 
4.4 
3 3-MeO-PCP-M (O-demethyl-piperidine-HO-) 276.1964 81.0701 (20), 84.0810 (18), 102.0913 
(99), 107.0490 (100), 175.1111 (54) 
4.0 
8 3-MeO-PCP-M (O-demethyl-piperidine-di-
HO-) 
292.1913 79.0545 (16), 84.0810 (18), 102.0914 
(100), 107.0491 (41), 173.0954 (58) 
3.1 
13 3-MeO-PCP-M (piperidine-di-HO-) 306.2069 81.0701 (23), 101.0597 (14), 
118.0860 (25), 121.0645 (100), 
189.1266 (48) 
5.1 
24 3-MeO-PCP-M (cyclohexyl-HO-piperidine-di-
HO-) 
322.2018 79.0545 (41.88), 101.0597 (34), 
118.0861 (66), 121.0645 (68), 
187.1111 (100) 
4.3 
57 3-MeO-PCP-M (O-demethyl-) glucuronide 436.2335 81.0702 (10), 86.0966 (100), 
107.0491 (23), 141.0176 (9), 
175.1112 (22) 
4.0 
58 3-MeO-PCP-M (O-demethyl-aryl-HO-) 
glucuronide 
452.2284 81.0701 (8), 86.0966 (55), 123.0438 
(100), 191.1059 (76), 367.1369 (3) 
3.8 
59 3-MeO-PCP-M (O-demethyl-piperidine-HO-) 
glucuronide 
452.2284 84.0810 (56), 102.0914 (52), 
107.0491 (90), 175.1111 (37), 
278.1225 (100) 
4.0 
61 3-MeO-PCP-M (piperidine-HO-) glucuronide 466.2441 84.0810 (45), 102.0914 (38), 
121.0646 (100), 189.1268 (41), 
278.1225 (79) 
4.7 
32 3-MeO-PCPy-M (O-demethyl-) 246.1858 72.0812 (100), 81.0702 (16), 
107.0491 (86), 175.1112 (45), 
246.1844 (4) 
4.3 
38 3-MeO-PCPy-M (O-demethyl-pyrrolidine-di-
HO-) 
278.1756 70.0656 (14), 79.0546 (15), 88.0759 
(100), 107.0491 (38), 173.0956 (64) 
3.1 
39 3-MeO-PCPy-M (pyrrolidine-di-HO-) 292.1913 81.0702 (24), 87.0443 (9), 104.0706 
(18), 121.0646 (100), 189.1268 (46) 
5.0 
45 3-MeO-PCPy-M (cyclohexyl-HO-pyrrolidine-
di-HO-) 
308.1862 79.0545 (42), 87.0443 (29), 104.0706 
(57), 121.0646 (66), 187.1111 (100) 
4.1 
64 3-MeO-PCPy-M (O-demethyl-) glucuronide 422.2179 72.0812 (100), 81.0701 (11), 
107.0491 (27), 175.1112 (26), 
3.7 
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422.2160 (13) 
66 3-MeO-PCPy-M (O-demethyl-aryl-HO-) 
glucuronide 
438.2128 72.0812 (43), 81.0701 (8), 123.0438 
(100), 191.1059 (78), 367.1375 (3) 
3.5 
67 3-MeO-PCPy-M (O-demethyl-aryl-HO-
pyrrolidine-2-oxo-) glucuronide 
452.1920 81.0702 (8), 86.0603 (22), 123.0439 
(100), 149,0592 (9), 191.1060 (78) 
6.2 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structures of 3-MeO-PCP (a), 3-MeO-PCPy (b), PCP (c), and PCPy (d) 
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Fig. (2). Metabolic pathways of 3-MeO-PCP. Undefined positions of hydroxylation are indicated by unspecific bonds. Parent compound is marked by a 
box. Two arrows indicate a pathway that contains multiple metabolism steps. 
Accepted (uncorrected) for publication in Current Neuropharmacology (03 October 2016) 
	
2	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Metabolic pathways of 3-MeO-PCPy. Undefined positions of hydroxylation are indicated by unspecific bonds. Parent compound is marked by a 
box. Two arrows indicate a pathway that contains multiple metabolism steps. Structures in brackets are postulated intermediate metabolites. 
